Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBIT Margin: 2024-2025

Historic EBIT Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -258.26%.

  • Monte Rosa Therapeutics' EBIT Margin rose 2957.00% to -258.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.69%, marking a year-over-year change of. This contributed to the annual value of -107.26% for FY2024, which is N/A change from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported EBIT Margin of -258.26% as of Q3 2025, which was down 285.12% from -67.06% recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EBIT Margin registered a high of 51.85% during Q1 2025, and its lowest value of -3,284.49% during Q1 2024.
  • Moreover, its 2-year median value for EBIT Margin was -258.26% (2025), whereas its average is -645.66%.
  • Data for Monte Rosa Therapeutics' EBIT Margin shows a peak YoY soared of 333,634bps (in 2025) over the last 5 years.
  • Monte Rosa Therapeutics' EBIT Margin (Quarterly) stood at 21.44% in 2024, then soared by 2,957bps to -258.26% in 2025.
  • Its EBIT Margin was -258.26% in Q3 2025, compared to -67.06% in Q2 2025 and 51.85% in Q1 2025.